Impact of Raltegravir Intensification on HIV-1 viral latency in Patients with Previous Complete Viral Suppression: a 48 week randomized, controlled, open-label, proof-of-concept pilot clinical trial | Irsicaixa

Mida actual: 100%

idioma:

CONTINGUT

Impact of Raltegravir Intensification on HIV-1 viral latency in Patients with Previous Complete Viral Suppression: a 48 week randomized, controlled, open-label, proof-of-concept pilot clinical trial

Entitat finançadora: Merck & Co.

Entitat(s) participant(s): Fundació IrsiCaixa

Investigador(s) extern(s): J.M. Llibre

Otros participantes: Javier Martínez-Picado, Roger Paredes,

Epidemiologia MolecularRetrovirologia i Estudis Clínics (GREC)